Chronic Trypanosoma cruzi infection in the rat: cyclophosphamide-induced recovery of adjuvant arthritis correlates with changes in the levels of lymph node T-lymphocytes and class II+ cells.
We have previously reported that treatment with cyclophosphamide (Cy) reversed the partial resistance of chronically Trypanosoma cruzi-infected rats to adjuvant-induced arthritis (AA) and caused a slight enhancement of arthritis in controls, when given 48 h before induction. To ascertain whether this Cy effect could be associated with regional changes of immunocompetent cells, popliteal lymph nodes were studied for their T-cell subsets and cells carrying class II major histocompatibility (MHC) antigens (1-A and 1-E molecules). Analysis at the time of arthritis induction revealed that infected rats receiving Cy 48 h earlier appeared to have recovered from the inverse balance of major T-cell subsets and showed 1-E+ cells lowered to normal, whereas values from control rats remained unchanged by Cy treatment. Establishment of AA was associated with substantial changes in the phenotype of lymph node cells that drained the affected limb. Changes were equally recorded in control and infected arthritic rats, and consisted of a significant raise of CD4+ and I-A+ cells along with lowered numbers of CD8+ and I-E+ cells. Treatment with Cy lowered even further the levels of CD8+ cells, while causing no affectation in the number of CD4+ cells that remained increased as in the arthritic counterparts receiving no Cy. Comparative analysis of class II MHC+ cells in Cy-treated rats revealed an additional decrease of I-E+ cells in draining lymph nodes from infected and control rats, which coincided with a simultaneous increase in I-A+ cells in the uninfected group. It is suggested that a deletion of a regulatory T-cell subset as well as an improved presentation of arthritogenic peptides may at least underlie the Cy-induced enhancement of the arthritic response.
Didoli
G
G
Instituto de Inmunología, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe, Argentina.
Revelli
S
S
Davila
H
H
Ferro
M E
ME
Romero-Piffiguer
M
M
Bottasso
O
O
D000818:Animals; D001169:Arthritis, Experimental / Q000188:drug therapy*; D014355:Chagas Disease / Q000276:immunology*; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000494:pharmacology*; D005802:Genes, MHC Class II / Q000235:genetics*; D006183:H-2 Antigens / Q000032:analysis / Q000235:genetics; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D008198:Lymph Nodes / Q000276:immunology*; D051381:Rats; D016176:T-Lymphocyte Subsets / Q000187:drug effects; D013601:T-Lymphocytes / Q000276:immunology*
D006183:H-2 Antigens; D000949:Histocompatibility Antigens Class II; D003520:Cyclophosphamide